ClinicaliQ Trial Snapshot
- Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer’s Disease Dementia — Recruiting • Phase II • Neurology • NCT07284472.
- What is being tested: EXV-802 and EXV-801 are novel investigational agents being evaluated for their safety and efficacy in treating agitation symptoms in patients with Alzheimer's Disease dementia.
- Patient eligibility overview: The trial recruits participants with a confirmed diagnosis of Alzheimer's Disease dementia who experience clinically significant agitation as a primary symptom requiring treatment intervention.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
Eligibility Snapshot
- : 1. The participant is an adult male or female between the ages of 55 to 90 years inclusively, who can move around by themselves, with a walker or a wheelchair. 2. A previously established diagnosis of AD dementia. 3. The participant has clinically significant, moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization 4. The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation. 5. Caregiver who is able and willing to comply with all required study procedures and who is in contact with the participant at least on four individual days for at least two hours per day.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.